Vaxcyte Inc. (PCVX)
NASDAQ: PCVX · Biological Products, (No Diagnostic Substances) · San Carlos, CA
Our rating: Positive
Positive reaffirmed at $61.92, moderate conviction, November 5, 2026.
Breaks if: The Positive call is wrong if the lead program receives a complete response letter, a clinical hold, or a pivotal trial failure within the next 12 months — events that would likely be signaled by the stock falling more than 35% from today's $61.92 (below roughly $40) over any 252-trading-day window. The call is also strained if the next quarterly filing or management communication indicates cash runway under 12 months without a financing commitment already in place.
Key figures
| Market value | $8.8B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$1.1B |
| Free cash flow, last 12 months | −$974M |
| Price to earnings | n/a |
| Free cash flow yield | −11.1% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −42.7% |
| Beta to the S&P 500 | 0.85 |
| Volatility, annualized | 64.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-1.99 | −$227M |
| June 30, 2026 | n/a | n/a | $-1.97 | −$237M |
| March 31, 2026 | n/a | n/a | $-2.30 | −$283M |
| December 31, 2025 | n/a | n/a | $-1.80 | −$227M |
| September 30, 2025 | n/a | n/a | $-1.56 | −$147M |
| June 30, 2025 | n/a | n/a | $-1.22 | −$123M |
| March 31, 2025 | n/a | n/a | $-1.04 | −$172M |
| December 31, 2024 | n/a | n/a | $-1.02 | −$115M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 2%, Gemini 2%, Mistral 2%
- Free cash flow for the quarter is above zero: Claude 3%, Gemini 2%, Mistral 3%
15 ledger entries and 23 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.